Abstract: The present disclosure relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), the method comprising the steps of a) extracting bacterial EV from the biofluid, b) analyzing the bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein the disease marker is a disease-specific molecular pattern of the subject; and the subject comprising patients diagnosed with HIV, IBD or cancer or the subject receiving a treatment.

Abstract: This disclosure relates to the field of research and clinical usage of extracellular vesicles. More in particular, this disclosure relates to usages of recombinant extracellular vesicles comprising a) a self-assembling protein that directs its own release through vesicles as a luminal membrane-bound protein and b) a heterologous marker. Indeed, the disclosure provides recombinant extracellular vesicles that can be used as a biological reference material in methods to quantify extracellular vesicles in a sample, and/or, that can be used to calibrate a device for sample extracellular vesicles analysis, and/or, that can be used to evaluate the isolation process of extracellular vesicles. This disclosure thus relates to improving the accuracy of an extracellular vesicle-based diagnosis.

Abstract: The present disclosure relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), the method comprising the steps of a) extracting bacterial EV from the biofluid, b) analyzing the bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein the disease marker is a disease-specific molecular pattern of the subject; and the subject comprising patients diagnosed with HIV, IBD or cancer or the subject receiving a treatment.

Abstract: This disclosure relates to the field of research and clinical usage of extracellular vesicles. More in particular, this disclosure relates to usages of recombinant extracellular vesicles comprising a) a self-assembling protein that directs its own release through vesicles as a luminal membrane-bound protein and b) a heterologous marker. Indeed, the disclosure provides recombinant extracellular vesicles that can be used as a biological reference material in methods to quantify extracellular vesicles in a sample, and/or, that can be used to calibrate a device for sample extracellular vesicles analysis, and/or, that can be used to evaluate the isolation process of extracellular vesicles. This disclosure thus relates to improving the accuracy of an extracellular vesicle-based diagnosis.

Abstract: The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer.

Abstract: The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer.